OncoMatch/Clinical Trials/NCT03184753
Genetically Modified T Cells Against Ovarian Cancer
Is NCT03184753 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies OC-IgT cells for ovarian cancer.
Treatment: OC-IgT cells — The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: salvage treatment — for first recurrence
Complete remission after salvage treatment for first recurrence
Cannot have received: gene-engineered T cell therapy
Previous experience of gene-engineered T cell therapy
Cannot have received: investigational drug
Exception: within the 28-day period prior to Day 0
Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study
Lab requirements
Blood counts
ANC ≥ 1000/mm3; Platelets ≥ 100,000/mm3; Hb ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 2 x ULN; Urine dipstick for proteinuria < 2+ or < 1 g/24 hr if ≥ 2+
Liver function
Serum bilirubin ≤ 2 x ULN (2.0 is acceptable in Gilbert's syndrome); AST/ALT ≤ 2 x ULN; Alkaline phosphatase ≤ 5 x ULN
Adequate bone marrow reserve with ·absolute neutrophil count (ANC) ≥ 1000/mm3. ·Platelets ≥100,000/mm3. Adequate renal and hepatic function with ·Serum creatinine ≤ 2 x upper limit of normal (ULN). ·Serum bilirubin ≤ 2 x ULN. * aspartate aminotransferase (AST)/ALT ≤ 2 x ULN. * Alkaline phosphatase ≤ 5 x ULN. * Serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome. Exclusion: Inadequate bone marrow function: ·Absolute neutrophil count < 1.0 x 10^9/L. * Platelet count < 100 x 10^9/L. * Hb < 9 g/dL. Inadequate liver and renal function: * Serum (total) bilirubin > 1.5 x ULN. * AST & ALT > 2.5 x ULN (> 5 x ULN in patients with liver metastases). * Alkaline phosphatase > 2.5 x ULN (or > 5 x ULN in case of liver metastases or > 10 x ULN in case of bone metastases). * Serum creatinine >2.0 mg/dl (> 177 μmol/L). * Urine dipstick for protein uria should be < 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate < 1 g of protein/24 hr.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03184753 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene-engineered T cell therapy, investigational drug disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages